Omitting endocrine therapy in ER-low breast cancer was associated with a 23% relative increase in the risk of death in 3 ...

HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer ... determining the hormone receptor and HER2 protein status, healthcare teams use the TNM system to identify ...

Medically reviewed by Marla Anderson, MD If you have HER2-positive breast cancer, your options for treatment will depend on ...

Triple-positive breast cancer, the diagnosis Thurston received, is estrogen receptor-positive, progesterone receptor-positive and HER2 (human epithelial growth factor receptor 2)-positive.

Estrogen receptor-positive (ER+) breast cancer, which makes up around 70% of all breast cancer cases, often becomes resistant to current hormone therapies. Now, researchers have designed and ...

today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive ...

Researchers have found new compounds that could be used to treat a common breast cancer that can be resistant to hormone therapies, outlined in a paper published in the journal RSC Medicinal Chemistry ...

Brain metastases become more prevalent with each line of therapy in metastatic breast cancer and are more common in patients with certain cancer subtypes, new research shows.

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...